[{"id":"1356603e-b2dd-488c-b74a-f432af18b9a1","acronym":"DDRiver Solid Tumours 301","url":"https://clinicaltrials.gov/study/NCT04170153","created_at":"2021-06-11T21:52:37.231Z","updated_at":"2025-02-25T12:27:22.944Z","phase":"Phase 1","brief_title":"Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)","source_id_and_acronym":"NCT04170153 - DDRiver Solid Tumours 301","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" ARID1A • ATRX","pipe":" | ","alterations":" ATM mutation • ARID1A mutation","tags":["ARID1A • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • tuvusertib (M1774)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 161","initiation":"Initiation: 12/20/2019","start_date":" 12/20/2019","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-24"},{"id":"a3ff3bf1-6fbc-4e00-b8e0-454d7fb78cce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687136","created_at":"2023-01-18T15:59:53.342Z","updated_at":"2025-02-25T13:41:23.007Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors","source_id_and_acronym":"NCT05687136","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18","pipe":" | ","alterations":" ATM mutation • ARID1A mutation","tags":["ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/07/2024","start_date":" 06/07/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-02-21"},{"id":"e17de7f3-6ed2-44ac-8c1d-acf78b25a29e","acronym":"NCI-2017-02296","url":"https://clinicaltrials.gov/study/NCT03375307","created_at":"2021-01-18T16:39:30.359Z","updated_at":"2025-02-25T13:39:36.028Z","phase":"Phase 2","brief_title":"Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes","source_id_and_acronym":"NCT03375307 - NCI-2017-02296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC","pipe":" | ","alterations":" FANCG mutation","tags":["TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FANCG mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/16/2025","study_completion_date":" 12/16/2025","last_update_posted":"2025-02-21"},{"id":"78af9b6a-0b92-4e92-b86c-385f5f7643c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04266912","created_at":"2021-01-18T20:43:57.460Z","updated_at":"2025-02-25T14:15:34.609Z","phase":"Phase 1/2","brief_title":"Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors","source_id_and_acronym":"NCT04266912","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-18"},{"id":"64ec7fee-f0ad-4556-bc3c-857c74e02812","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145115","created_at":"2021-07-05T17:26:08.613Z","updated_at":"2025-02-25T14:07:33.392Z","phase":"Phase 2","brief_title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","source_id_and_acronym":"NCT04145115","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type","tags":["EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2025-02-17"},{"id":"dff546be-9a9d-4936-8524-d7a95d167ef0","acronym":"FORESEE","url":"https://clinicaltrials.gov/study/NCT06406387","created_at":"2024-05-09T20:29:53.236Z","updated_at":"2025-02-25T16:34:09.927Z","phase":"","brief_title":"ATRX/DAXX in EUS-FNB Specimens of Pan-NETs","source_id_and_acronym":"NCT06406387 - FORESEE","lead_sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","biomarkers":" ATRX • DAXX","pipe":"","alterations":" ","tags":["ATRX • DAXX"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 03/30/2025","primary_completion_date":" 03/30/2025","study_txt":" Completion: 11/30/2029","study_completion_date":" 11/30/2029","last_update_posted":"2025-02-07"},{"id":"6365efdc-854e-4454-ba10-f28f09a5a11b","acronym":"PEPN2112","url":"https://clinicaltrials.gov/study/NCT05071209","created_at":"2021-10-08T11:53:44.641Z","updated_at":"2025-02-25T17:01:24.348Z","phase":"Phase 1/2","brief_title":"Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT05071209 - PEPN2112","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3","pipe":" | ","alterations":" PAX3-FOXO1 fusion","tags":["BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PAX3-FOXO1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elimusertib (BAY 1895344)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/22/2021","start_date":" 12/22/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 11/22/2025","study_completion_date":" 11/22/2025","last_update_posted":"2025-02-03"},{"id":"4d0aa8dd-1906-440f-bdc4-7b7bd07db44b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05076513","created_at":"2021-10-13T16:58:18.037Z","updated_at":"2025-02-25T13:12:47.827Z","phase":"Phase 1","brief_title":"Trial of Niraparib in Participants with Newly-diagnosed Glioblastoma and Recurrent Glioma","source_id_and_acronym":"NCT05076513","lead_sponsor":"Nader Sanai","biomarkers":" IDH1 • IDH2 • ATRX","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 03/19/2024","primary_completion_date":" 03/19/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-01-23"},{"id":"254804cf-c50f-409d-b809-0f0a4043dc18","acronym":"CL1-95032-005","url":"https://clinicaltrials.gov/study/NCT05484622","created_at":"2022-08-02T12:55:57.680Z","updated_at":"2025-02-25T16:18:00.683Z","phase":"Phase 1","brief_title":"Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma","source_id_and_acronym":"NCT05484622 - CL1-95032-005","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • ATRX","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Voranigo (vorasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 01/20/2023","start_date":" 01/20/2023","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 08/30/2027","study_completion_date":" 08/30/2027","last_update_posted":"2025-01-14"},{"id":"dfa37710-8128-4c60-aefe-7507a106a2e0","acronym":"MK3475-A53","url":"https://clinicaltrials.gov/study/NCT05379972","created_at":"2022-05-18T11:57:02.291Z","updated_at":"2025-02-25T16:17:42.708Z","phase":"Phase 2","brief_title":"Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers","source_id_and_acronym":"NCT05379972 - MK3475-A53","lead_sponsor":"University of Colorado, Denver","biomarkers":" HER-2 • BRCA1 • BRCA2 • PTEN • HRD • BAP1 • KMT2D • ATRX • CHEK2 • FANCA • BRIP1 • RAD50 • MLL2 • CHEK1 • BARD1 • NBN • WRN • FANCG • ABRAXAS1 • SLX4","pipe":" | ","alterations":" HRD","tags":["HER-2 • BRCA1 • BRCA2 • PTEN • HRD • BAP1 • KMT2D • ATRX • CHEK2 • FANCA • BRIP1 • RAD50 • MLL2 • CHEK1 • BARD1 • NBN • WRN • FANCG • ABRAXAS1 • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 01/12/2023","start_date":" 01/12/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-11-26"},{"id":"0c02cc4f-da25-44d0-b391-3f1638d91362","acronym":"AMPLIFY-NEOVAC","url":"https://clinicaltrials.gov/study/NCT03893903","created_at":"2021-01-18T19:10:49.432Z","updated_at":"2024-07-02T16:34:38.157Z","phase":"Phase 1","brief_title":"AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma","source_id_and_acronym":"NCT03893903 - AMPLIFY-NEOVAC","lead_sponsor":"German Cancer Research Center","biomarkers":" ATRX","pipe":" | ","alterations":" IDH1 R132","tags":["ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • IDH1R132H peptide vaccine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/19/2018","start_date":" 10/19/2018","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-05"},{"id":"72596fa1-a0d4-4a25-9d18-6edd6d556738","acronym":"","url":"https://clinicaltrials.gov/study/NCT05505825","created_at":"2024-03-25T18:36:13.170Z","updated_at":"2024-07-02T16:35:01.060Z","phase":"Phase 1/2","brief_title":"A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer","source_id_and_acronym":"NCT05505825","lead_sponsor":"Akeso","biomarkers":" ATRX","pipe":" | ","alterations":" ATRX mutation","tags":["ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kaitanni (cadonilimab) • Auraza (chiauranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/26/2022","start_date":" 08/26/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-24"},{"id":"f976983e-6e5c-40aa-ba00-71e22eb80e0e","acronym":"ATRIUM","url":"https://clinicaltrials.gov/study/NCT05338346","created_at":"2022-04-21T15:55:20.706Z","updated_at":"2024-07-02T16:35:08.451Z","phase":"Phase 1","brief_title":"A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies","source_id_and_acronym":"NCT05338346 - ATRIUM","lead_sponsor":"Antengene Discovery Limited","biomarkers":" BRCA1 • BRCA2 • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" TP53 mutation • FANCF mutation","tags":["BRCA1 • BRCA2 • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FANCF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATG-018"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 07/08/2022","start_date":" 07/08/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-22"},{"id":"83026695-d43a-4653-bca6-29f8b4ee5021","acronym":"REVOLUMAB","url":"https://clinicaltrials.gov/study/NCT03925246","created_at":"2021-01-18T19:18:33.109Z","updated_at":"2025-02-25T14:28:20.050Z","phase":"Phase 2","brief_title":"Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas","source_id_and_acronym":"NCT03925246 - REVOLUMAB","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" PD-L1 • TMB • IDH1 • IDH2 • MGMT • CD8 • PD-1 • ATRX • CD163 • CD4 • CD68 • FOXP3 • GFAP • OLIG2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • IDH1 R132","tags":["PD-L1 • TMB • IDH1 • IDH2 • MGMT • CD8 • PD-1 • ATRX • CD163 • CD4 • CD68 • FOXP3 • GFAP • OLIG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • temozolomide"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 07/30/2019","start_date":" 07/30/2019","primary_txt":" Primary completion: 12/02/2020","primary_completion_date":" 12/02/2020","study_txt":" Completion: 08/18/2021","study_completion_date":" 08/18/2021","last_update_posted":"2024-04-02"},{"id":"ae2fbbdf-1d9d-47eb-9888-dad360517475","acronym":"MATRIX","url":"https://clinicaltrials.gov/study/NCT05986071","created_at":"2023-08-14T15:09:50.416Z","updated_at":"2025-02-25T16:19:00.084Z","phase":"Phase 1/2","brief_title":"I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers","source_id_and_acronym":"NCT05986071 - MATRIX","lead_sponsor":"Institut Paoli-Calmettes","biomarkers":" HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1","pipe":" | ","alterations":" HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation","tags":["HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • tuvusertib (M1774)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 10/15/2027","study_completion_date":" 10/15/2027","last_update_posted":"2024-03-29"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"caba8d6b-3a99-4cf4-a5f0-d1c3cfbe3575","acronym":"","url":"https://clinicaltrials.gov/study/NCT03343197","created_at":"2021-01-18T16:30:40.675Z","updated_at":"2024-07-02T16:35:17.668Z","phase":"Phase 1","brief_title":"Study of AG-120 and AG-881 in Subjects With Low Grade Glioma","source_id_and_acronym":"NCT03343197","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • ATRX","pipe":" | ","alterations":" ATRX mutation • IDH1 R132H • IDH1 R132","tags":["IDH1 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Voranigo (vorasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 03/20/2018","start_date":" 03/20/2018","primary_txt":" Primary completion: 08/02/2019","primary_completion_date":" 08/02/2019","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-02-26"},{"id":"d6f097ba-9519-4376-8dfc-112499960700","acronym":"","url":"https://clinicaltrials.gov/study/NCT02840409","created_at":"2021-01-18T13:56:34.086Z","updated_at":"2024-07-02T16:35:21.598Z","phase":"Phase 2","brief_title":"Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)","source_id_and_acronym":"NCT02840409","lead_sponsor":"The Hospital for Sick Children","biomarkers":" BRAF • FGFR1 • NTRK2 • NF1 • PTPN11 • ATRX • RAF1 • H3-3A • MYBL1","pipe":" | ","alterations":" BRAF mutation • FGFR1 fusion","tags":["BRAF • FGFR1 • NTRK2 • NF1 • PTPN11 • ATRX • RAF1 • H3-3A • MYBL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • FGFR1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • vinblastine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-01-31"},{"id":"40c5a9dd-b0cf-48c4-bf22-51d4452040b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03448718","created_at":"2021-01-18T17:00:17.468Z","updated_at":"2025-02-25T14:58:45.009Z","phase":"Phase 2","brief_title":"Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations","source_id_and_acronym":"NCT03448718","lead_sponsor":"Matthew Galsky","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/17/2018","start_date":" 04/17/2018","primary_txt":" Primary completion: 07/14/2021","primary_completion_date":" 07/14/2021","study_txt":" Completion: 10/15/2021","study_completion_date":" 10/15/2021","last_update_posted":"2023-11-22"},{"id":"12b373a9-f27e-4aa8-b2c5-2cb259826f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03718091","created_at":"2021-01-18T18:13:18.198Z","updated_at":"2024-07-02T16:35:43.598Z","phase":"Phase 2","brief_title":"M6620 (VX-970) in Selected Solid Tumors","source_id_and_acronym":"NCT03718091","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2023-07-07"},{"id":"58449b51-d1f8-458f-8290-5350013047d8","acronym":"MS201922-0001","url":"https://clinicaltrials.gov/study/NCT02278250","created_at":"2021-01-18T10:43:33.755Z","updated_at":"2025-02-25T16:14:08.887Z","phase":"Phase 1","brief_title":"First in Human Study of M4344 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02278250 - MS201922-0001","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" ARID1A • ATRX","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gartisertib (M4344)"],"overall_status":"Completed","enrollment":" Enrollment 97","initiation":"Initiation: 01/26/2015","start_date":" 01/26/2015","primary_txt":" Primary completion: 06/16/2021","primary_completion_date":" 06/16/2021","study_txt":" Completion: 09/24/2021","study_completion_date":" 09/24/2021","last_update_posted":"2023-03-16"},{"id":"354dc2c5-feeb-41d3-8c1c-e0fb0c8edd00","acronym":"IMPARP-HRD","url":"https://clinicaltrials.gov/study/NCT04985721","created_at":"2021-08-02T14:53:05.727Z","updated_at":"2024-07-02T16:35:53.270Z","phase":"Phase 2","brief_title":"A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects","source_id_and_acronym":"NCT04985721 - IMPARP-HRD","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" BRCA1 • BRCA2 • ATM • HRD • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • FANCL • WRN • FANCI • FANCM • FANCG","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD","tags":["BRCA1 • BRCA2 • ATM • HRD • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • FANCL • WRN • FANCI • FANCM • FANCG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/24/2022","start_date":" 02/24/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-03-15"},{"id":"b779fc61-9ce2-46a0-bf31-8408e99ed716","acronym":"","url":"https://clinicaltrials.gov/study/NCT05010096","created_at":"2021-08-18T15:53:42.006Z","updated_at":"2024-07-02T16:36:09.743Z","phase":"Phase 1b","brief_title":"BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05010096","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PIK3CA • BRCA1 • BRCA2 • PTEN • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" PIK3CA mutation • ATM mutation • PTEN mutation • ATM deletion • ATM expression","tags":["PIK3CA • BRCA1 • BRCA2 • PTEN • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • ATM mutation • PTEN mutation • ATM deletion • ATM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aliqopa (copanlisib) • elimusertib (BAY 1895344)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 03/22/2022","primary_completion_date":" 03/22/2022","study_txt":" Completion: 03/22/2022","study_completion_date":" 03/22/2022","last_update_posted":"2022-05-27"},{"id":"f1218a46-8327-4435-bd08-23987da118e2","acronym":"GLIOLIPSY","url":"https://clinicaltrials.gov/study/NCT05133154","created_at":"2021-11-25T00:36:03.963Z","updated_at":"2024-07-02T16:36:17.264Z","phase":"","brief_title":"LIQUID BIOPSY IN Low-grade Glioma Patients","source_id_and_acronym":"NCT05133154 - GLIOLIPSY","lead_sponsor":"University Hospital, Montpellier","biomarkers":" ATRX","pipe":"","alterations":" ","tags":["ATRX"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/05/2022","start_date":" 01/05/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2022-02-10"}]